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Background: Serum preptin levels among subjects with different bone mineral densities (BMD) were measured
and investigated to determine the correlation between BMD and bone-metabolic markers.
Methods: Approximately 52 elderly male patients with osteoporosis, 50 elderly men with osteopaenia, and 31
age-matched normal bone mass controls participated in the study. The serum preptin levels and bone metabolic
markers were measured by enzyme-linked immunosorbent assay. The relationships between preptin levels, BMD,
and metabolic parameters were also assessed.
Results: The serum preptin level was the lowest in the osteoporosis group and positively correlated with BMD. All
the bone formation markers in the osteoporosis and osteopaenia groups were significantly reduced compared with
those in the normal group. Serum preptin level was positively correlated with all the bone formation markers,
whereas no correlation was observed with the bone resorption marker TRACP-5b.
Conclusions: Serum preptin levels are decreased in osteoporosis and osteopaenia patients and positively correlated
with BMD. Therefore, preptin is involved in the pathogenesis of osteoporosis, probably through bone formation
rather than bone resorption.
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Bone remodelling is essential for adult bone homoeosta-
sis. The failure of this process often leads to the develop-
ment of osteoporosis, a current major global health
concern [1]. The most important factor that affects nor-
mal bone remodelling is the tightly controlled and
orchestrated regulation of osteoblasts and osteoclasts.
Any disturbance in this balance causes various bone dis-
eases, including osteoporosis, which is characteristically
defined as decreases bone density with high risk of frac-
ture [2,3]. Anti-resorption agents are considered in the
rebuilding of the bone remodelling balance because
postmenopausal osteoporosis (type I) is characterised by
bone resorption that exceeds bone formation. By con-
trast, the characterisation of senile osteoporosis (type II)* Correspondence: jiehancn@126.com
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reproduction in any medium, provided the oris reduced bone formation, whereas bone resorption is
nearly stable. Thus, stimulating bone formation is an-
other way of treating osteoporosis [4].
Recent advances and increased knowledge in the regu-
lation of osteoblastic bone development and bone mass
maintenance have enhanced the current understanding
on why variations in normal osteoblastogenesis regula-
tion induces bone diseases [5,6]. Further studies on the
regulatory factors promote the discovery of therapeutic
targets for stimulating bone formation, and when com-
bined with other therapies, provide the ultimate treat-
ment for osteoporosis [7-10]. Preptin, cosecreted with
insulin and amylin from β-cells [11,12], is a 34–amino
acid peptide that corresponds to Asp69–Leu102 of the
proinsulin-like growth factor IIE-peptide (pro-IGF-IIE)
[12,13]. Preptin is a physiologic amplifier of glucose-
mediated insulin secretion. Elevated plasma preptin
levels in newly diagnosed patients with type 2 diabetes
mellitus (T2DM) suggest that preptin participates in thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical characteristics of study subjects (Data are mean±SD)
Groups Cases (n) Age (y) Height (m) Weight (kg) BMI (kg/m2)
Osteoporosis 52 78.07 ± 4.61 1.64 ± 0.06 59.86 ± 6.17 22.34 ± 1.84
Osteopenia 50 77.94 ± 4.51 1.64 ± 0.06 61.14 ± 5.42 22.79 ± 1.29
Normal bone mass 31 77.15 ± 3.76 1.66 ± 0.06 61.54 ± 5.00 22.42 ± 1.55
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blast proliferation and reduces osteoblast apoptosis. Pre-
ptin administration increases bone area and mineralising
surface in adult mice [15]. Therefore, preptin is involved
in bone anabolism and contributes to the bone mass
preservation observed in hyperinsulinaemic states, such
as obesity [15]. These initial results obtained in animals
and human diabetes patients led us to investigate circu-
lating preptin levels in human osteoporosis. In the
present study, serum preptin levels were measured in
male subjects with different bone mineral density
(BMD), in order to exclude the influence of type I osteo-
porosis. We also assessed the association between serum
preptin levels, BMD, and several metabolic parameters
in these subjects.Methods
Subjects
133 elderly men participated in the study. All study sub-
jects were of Han Chinese origin and lived in the same
region of the country. The subjects had no history of
T2DM, no clinical evidence of any major diseases, and
they were selected from the participants who had under-
gone routine medical check-ups from Jun 2011 to Aug
2011. None of the subjects was taking any medication
that affects bone metabolism. Candidates with body
mass indices (BMI) <18.5 kg/m2 or BMI > 25 kg/m2
were all excluded. Age and BMI matched control sub-
jects were selected. This study was conducted in accord-
ance with the declaration of Helsinki. This study was
conducted with approval from the Ethics Committee of
Shanghai East Hospital affiliated of Tong Ji University.
Written informed consent was obtained from all
participants.
Bone mineral density (BMD)
Dual-energy X-ray absorptiometry (DXA, GE Lunar
Prodigy, US) was used to determine the BMD in theTable 2 BMD comparison among the three groups (Data are m
Groups Cases (n) L2-4 (g/cm
2)
Osteoporosis 52 0.826 ± 0.080##
Osteopenia 50 1.059 ± 0.066##*
Normal bone mass 31 1.338 ± 0.140**
Note: compared with the normal bone mass group, # p<0.05, ## p<0.01; comparedanteroposterior L2–4 lumbar spine, left femoral neck,
and left total hip of the subjects. All cases were then
divided into a normal bone mass group (n = 31), an
osteopaenia group (n = 50), and an osteoporosis group
(n = 52) according to BMD (anyone of L2-4, left femoral
neck, or left total hip).
The World Health Organization (WHO) defines
osteoporosis based on the BMD measurement [16].
Osteopaenia is defined as a BMD between 1 stand-
ard deviation (SD) and 2.5 SDs below the mean for
young adults (i.e., the T score), whereas osteoporosis
is defined as a BMD of >2.5 SDs below the mean for
young adults [12]. This definition was developed for
Caucasian postmenopausal women but it appears to
be valid in men as well [17].
Enzyme-linked immunosorbent assay (ELISA)
The serum concentration of preptin was determined by
ELISA (R&D, USA). The linear range of the assay was
0.3 ng/mL to 10 ng/mL. Bone formation markers [serum
bone alkaline phosphatase (B-ALP), bone Gla protein
(BGP), procollagen type I amino-terminal propeptide
(PINP)], and bone resorption item tartrate-resistant acid
phosphatase-5b (TRACP-5b) were determined by ELISA
according to manufacturers’ instructions.
Statistical analysis
The data are shown as mean ± SD. All statistical ana-
lyses were performed using the SPSS 18.0 software (SPSS
Inc., Chicago, IL, USA). The baseline characteristics of
the test and the control subjects were compared by one-
way ANOVA, Wilcoxon rank-sum test, or chi-square
test. The general linear modelling function analysis was
used to control potential confounders. As our primary
approach, the serum preptin concentrations were
included as continuous independent variables in the
multivariate models. Simple and multiple regression ana-
lyses were used to examine the association between
serum preptin concentrations and the other biomarkers.ean±SD)
Femur Neck (g/cm2) Total hip (g/cm2)
0. 598 ± 0.116## 0.698 ± 0.125##
* 0.769 ± 0.158##** 0.859 ± 0.154#**
0.896 ± 0.182** 0.968 ± 0.194**
with the osteoporosis group, ** p<0.01.
Table 3 Serum preptin levels (Data are mean±SD)
Groups Cases (n) Preptin (ng/mL)
Osteoporosis 52 5.10 ± 0.69##
Osteopenia 50 7.09 ± 1.36##**
Normal bone mass 31 10.11 ± 1.61**
Note: compared with the normal bone mass group, ## p<0.01; compared with




























































Figure 1 There existed significantly positive correlation
between serum preptin levels and all three BMD, that is,
preptin levels correlated positively with L2-4 BMD (P <0.001),
femur neck BMD (P <0.001), and total hip BMD (P <0.001).
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P < 0.05 was considered significant.
Results
General data
The clinical characteristics of the subjects are shown in
(Table 1). No significant difference was observed be-
tween the age, body height, weight, and BMI in all three
groups (p > 0.05). Thus, the ages, body height, weight,
and BMI were all matched.
Bone mineral density and serum preptin levels
We compared the BMD among the three groups. The
L2-4, femur neck and total hip BMD of osteoporosis
group were all lower than those of the osteopaenia
group (P < 0.01). The same results could be seen be-
tween the osteopaenia group and the normal bone mass
group (Table 2).
The serum preptin levels were further compared. The
serum preptin level of the osteoporosis group was lower
compared with that of the osteopaenia group (5.10 ng/
mL ± 0.69 ng/mL vs. 7.09 ng/mL ± 1.36 ng/mL,
P < 0.01). The serum preptin level of the osteopaenia
group was lower compared with that of the normal
bone mass group (7.09 ng/mL ± 1.36 ng/mL vs. 10.11
ng/mL ± 1.61 ng/mL, P < 0.01) (Table 3).
The preptin levels correlated positively with the L2-4
BMD (P < 0.001), the femur neck BMD (P < 0.001), and
the total hip BMD (P < 0.001) (Figure 1). Serum preptin
levels correlated with BMD was after adjusting for age
and BMI.
Bone turnover and other biochemical parameters:
correlation with preptin levels
The bone formation markers (B-ALP, BGP, and PINP) of
the osteoporosis group were all lower than those of the
osteopaenia group, and those of the osteopaenia group
were lower than those in the normal bone mass group
(Figure 2).
The serum preptin levels correlated positively with B-
ALP (r = 0.212, p = 0.014), BGP (r = 0.699, P < 0.001),
and PINP (r = 0.266, p = 0.002), which was after adjust-
ing for age and BMI.
No significant difference was observed in the bone
resorption marker TRACP-5b among the three groups(P > 0.05). No correlation was observed with preptin
levels (r = −0.018, p = 0.841).
Discussion
Osteoporosis is characterised by low bone mass accom-
panied by bone microarchitectural changes that increase
Figure 2 The serum preptin levels correlated positively with all of the three bone formation items (B-ALP, p<0.05; BGP, P <0.001; PINP,
P <0.01).
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between bone formation and resorption is critical for the
maintenance of bone mass density (BMD) and systemic
mineral homoeostasis [1,2]. Osteoporosis is mainly
caused by bone remodelling failure, which is regulated
by many factors [20-25].
As a novel hormone, preptin increases the bone area
and mineralising surface in adult mice by stimulating
osteoblast proliferation and reducing osteoblast apop-
tosis [15]. Therefore, preptin is involved in bone anabol-
ism and contributes to bone mass preservation [15].
However, the function and mechanism of preptin in
human osteoporosis remain unclear.
The current study found that preptin levels are corre-
lated with BMD. The preptin level was the lowest in
osteoporosis patients than in osteopaenia and normal
bone mass subjects. The present study is the first to in-
vestigate preptin levels in subjects with different BMDs.
Bone formation markers were reduced in elderly male
patients with osteoporosis and positively correlated with
preptin levels. However, the bone resorption marker was
not correlated with preptin levels. Lower circulating pre-
ptin was correlated with reduced osteogenesis, which is
consistent with the characteristics of Type II (senile)
osteoporosis (reduced bone formation and low bone
turnover). Hence, preptin may be involved in Type II
osteoporosis by affecting bone formation. Understanding
these mechanisms will facilitate further research on boneremodelling and osteoporosis. Future investigations on
the endogenous regulation of osteoblastogenesis will
increase the current knowledge for developing potential
drug targets for treating osteoporosis.
The present study has limitations that need to be con-
sidered. The cross-sectional design limits our ability to
infer a causal relationship between reduced serum pre-
ptin level and low BMD. Our analyses are based on
a single blood preptin measurement, which does not
reflect the relationship between preptin levels and BMD
over time. Measuring serial changes in blood preptin
levels in preosteoporotic and osteoporotic subjects will
further clarify the role of preptin in the pathogenesis of
osteoporosis. Furthermore, the effects of oestrogen were
not included. Hence, postmenopausal osteoporotic
patients were excluded from the present study. Detect-
ing the blood preptin levels in females and comparing
them with male osteoporotic patients will help elucidate
the differences in pathogenesis of osteoporosis between
males and females.
Diabetes mellitus (DM) alters bone remodelling,
and osteopaenia and osteoporosis are among its
complications. High extracellular glucose concentra-
tions act as an endogenous factor that increases bio-
mineralisation degree but reduces mineral quality
[23]. Preptin functions in the pathogenesis of Type
II DM [14]. Thus, subjects with DM or hypergly-
caemia were excluded.
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The lower blood preptin levels in elderly male patients
with osteoporosis suggest that preptin has a function in
the pathogenesis of Type II osteoporosis. However, this
finding needs to be clarified in further studies. Further
in vivo experiments should determine whether preptin is
a new target for treating osteoporosis by promoting
bone formation.
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